PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Only One in Five Young Adults Adhere After First Psychosis

antipsychoticslong-acting injectablesfirst-episode psychosisschizophreniamedication adherenceproportion of days coveredhealth care utilizationclaims analysisretrospective cohortpsychiatry Psychiatry / Psychopharmacology

Background Information

First-episode psychosis patients show alarmingly low antipsychotic adherence.

Understanding medication adherence in early psychosis is crucial for improving long-term outcomes and reducing health care burdens. Only 19.1% of individuals adhered to antipsychotics, with better adherence linked to fewer emergency department (ED) visits. Low adherence to antipsychotics among first-episode psychosis patients underscores the need for targeted interventions to enhance medication compliance and improve treatment outcomes. Improving antipsychotic adherence in first-episode psychosis could reduce ED visits and improve overall outcomes.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Chi E, Sridhar S, Montesano V, Ramos J, Breitborde NJK, Seiber EE

Citation: Chi E, Sridhar S, Montesano V, et al. Treatment Adherence and Health Care Utilization After a First Episode of Psychosis. JAMA network open. 2026;9(9):e2635805. doi:10.1001/jamanetworkopen.2026.35805

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.